T1	Participants 40 64	persistent genital warts
T2	Participants 383 429	conducted independently in Australia and China
T3	Participants 1033 1075	102 protocol compliant Brisbane recipients
T4	Participants 1689 1728	168 Wenzhou protocol compliant subjects
